COMP <GO>
ADVB vs ACON // EV/EBITDA & P/E VALUATION
Advanced Biomed Inc. (NASDAQ) VS. Aclarion Inc. (NASDAQ) • 15-METRIC TALLY: ADVB 1
— ACON 3
■ METRIC PARITY
LAST: $2.64 (-11.41%) • MKT CAP: $4.4M
valuation
—
LAST: $1.97 (-3.43%) • MKT CAP: $5.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADVB VS. ACON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADVB | ACON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 9.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -9.10% | -35.00% | +25.90 | ADVB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 65.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | ACON | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.4 | 39.0 | -18.63 | ACON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.4M | $5.7M | -$1.3M | ACON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADVB REV | ACON REV | ADVB GROSS % | ACON GROSS % | ADVB FCF | ACON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $75.7K | — | 9.0% | -$5.9M | -$7.2M |
| FY 2024 | $0 | $45.7K | — | -50.0% | -$2.2M | -$5.3M |
| FY 2023 | — | $75.4K | — | — | — | -$3.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADVB // BETA —
ACON // BETA —